FDA Grants Additional Time for Data Review

The U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for Capricor Therapeutics (CAPR)'s Biologics License Application (BLA) for delamiocel (development name CAP-1002) from August 22, 2026, to November 22, 2026. This extension followed the company's submission of 24-month data and robustness analysis from the long-term extension of its Phase 3 HOPE-3 trial, which the FDA classified as a Major Amendment. While approval has not been finalized, the FDA's decision to formally review the new efficacy data after the Complete Response Letter (CRL) issued on July 9, 2025, for insufficient evidence of effectiveness, indicates that the regulatory pathway remains intact. The commercial timeline has been delayed by three months, but this development is more favorable than an immediate second CRL.

Review Focus Shifts from Cardiomyopathy to Upper Limb Function

On July 29, 2026, the FDA advisory committee voted 3 in favor and 9 against the evidence supporting the treatment effect of delamiocel for Duchenne Muscular Dystrophy (DMD)-related cardiomyopathy. In response, Capricor shifted its focus from cardiomyopathy to a refined indication centered on the primary endpoint of the HOPE-3 trial: the Performance of Upper Limb 2.0 (PUL 2.0). In the 106-patient randomized, double-blind Phase 3 trial, the least squares mean percentage change in total PUL 2.0 score at 12 months showed a difference of 4.55 percentage points, with a 95% confidence interval of 0.47 to 8.63 and a p-value of 0.029. However, the FDA's internal analysis, depending on the statistical analysis plan version, reported a score difference of 0.66 and a p-value of 0.24, making statistical methodology and clinical relevance central to the final decision.

Delamiocel Has a Distinct Mechanism of Action from Existing DMD Therapies

Delamiocel is a Phase 3-stage allogeneic cardiosphere-derived cell (CDC) therapy composed of myocardial progenitor cells obtained from donor hearts suitable for transplantation. It does not directly block a single molecule but instead secretes extracellular vesicles, microRNA, and growth factors to modulate macrophage function, inducing anti-inflammatory, anti-fibrotic, and immunomodulatory effects. This mechanism differentiates it from Elevidys (delandistrogene moxeparvovec-rokl) by Sarepta Therapeutics and exon-skipping therapies, which aim to complement dystrophin expression. As a therapy requiring repeated intravenous administration, delamiocel offers long-term efficacy, manufacturing consistency, and repeat-dose safety as key commercial differentiators compared to one-time gene therapies.

Competitive Landscape and Partner Economics Are Tied to Approval

The global DMD treatment market is projected to grow from $5.43 billion in 2026 to $19.18 billion by 2034. Current standards include corticosteroids, heart failure medications, Elevidys, Agamree (vamorolone), Duvyzat (givinostat), and exon-skipping therapies. While Elevidys was first approved by the FDA on June 22, 2023, and its indication was expanded on June 20, 2024, it was later restricted in November 2025 to exclude non-ambulatory patients due to cases of acute liver failure and death. Delamiocel targets late-stage DMD patients regardless of genetic mutation, potentially filling a competitive gap. The commercial viability of Nippon Shinyaku (TSE:4516), Capricor's exclusive distribution partner in the U.S. and Japan, is directly linked to the FDA's November decision.